2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Melanoma
4
Low-grade Glioma
3
Pancreatic Neoplasms
2
Neoplasms
2
Glioma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Noonan Syndrome 5
1
Leukemia, Hairy Cell
1
Diffuse Intrinsic Pontine Glioma
1
Craniopharyngioma
1
Brain Neoplasms
1
Advanced Nonhematologic Malignancies
1
Interventions
Surgical Procedures, Operative
4
Magnetic Resonance Spectroscopy
3
Exenatide
3
tocilizumab
2
Temozolomide
2
Surveys and Questionnaires
2
Radiotherapy
2
Proton Therapy
2
Mental Status and Dementia Tests
2
Donepezil
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
trifluridine tipiracil drug combination
1
trametinib
1
tozuleristide
1
tovorafenib
1
temsirolimus
1
gallium Ga 68 dotatate
1
entinostat
1
dabrafenib
1
cobimetinib
1
carboxyamido-triazole
1
binimetinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
anlotinib
1
Verteporfin
1
Vemurafenib
1
Tumor Burden
1
Transurethral Resection of Bladder
1
Thalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Craniopharyngioma
×
tovorafenib
×
Clear all
NCT05465174
2026-04-23
PNOC029
University of California, San Francisco
Phase 2
Recruiting
57 enrolled